Information for patients

We are moving from promise to practice in the clinic.

View our clinical trials

ASG-22ME

About ASG-22ME

ASG-22ME is an antibody-drug conjugate (ADC) targeting Nectin-4, which can be found on multiple cancers, including bladder, breast, lung and pancreatic. The antibody is attached to a potent, synthetic cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology.

The linker system is designed to be stable in the bloodstream and release the cell-killing agent once inside target cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects patients may experience during treatment with traditional chemotherapy while enhancing the antitumor activity.

Status

We are co-developing ASG-22ME under an agreement with Agensys, an affiliate of Astellas. ASG-22ME is in a phase 1 clinical trial to evaluate the safety and antitumor activity of escalating doses of ASG-22ME in patients with solid tumors.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com